12 Nov 2020

Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

12 Nov 2020

Mycovia Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

02 Nov 2020

Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

21 Oct 2020

Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC)

21 Oct 2020

Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19